Travere Therapeutics (TVTX) Net Cash Flow (2011 - 2026)
Travere Therapeutics (TVTX) posted Net Cash Flow of -$14.6 million for Q1 2026, up 16.41% on a QoQ basis from -$17.5 million in Q4 2025, and down 619.3% year-over-year from $2.8 million in Q1 2025.
Travere Therapeutics (TVTX) Net Cash Flow (2011 - 2026) Analysis & Trends
Travere Therapeutics' Net Cash Flow history runs 16 years deep, the most recent figure standing at -$14.6 million for Q1 2026.
- Quarterly Net Cash Flow fell 619.3% year-over-year to -$14.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.8 million (down 20.59% YoY) and the FY2025 annual result came in at $32.2 million, up 2432.15% from the prior year.
- Net Cash Flow was -$14.6 million for Q1 2026 at Travere Therapeutics, up from -$17.5 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $91.8 million in Q1 2022 and bottomed at -$132.6 million in Q4 2023.
- A 5-year average of -$7.7 million and a median of -$11.0 million in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2025 — Net Cash Flow jumped 783.26% — and 2026, when it plunged 619.3%.
- Travere Therapeutics' Net Cash Flow stood at -$90.2 million in 2022, then tumbled by 47.07% to -$132.6 million in 2023, then jumped by 117.14% to $22.7 million in 2024, then tumbled by 176.92% to -$17.5 million in 2025, then increased by 16.41% to -$14.6 million in 2026.
- Business Quant data shows TVTX's Net Cash Flow at -$14.6 million in Q1 2026, -$17.5 million in Q4 2025, and $35.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn | -14.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.61 Mn |
| Mar 31, 2026 | -14.61 Mn |
| Dec 31, 2025 | -17.48 Mn |
| Dec 31, 2025 | -17.48 Mn |
| Sep 30, 2025 | 35.57 Mn |
| Sep 30, 2025 | 35.57 Mn |
| Jun 30, 2025 | 11.31 Mn |
| Jun 30, 2025 | 11.31 Mn |
| Mar 31, 2025 | 2.81 Mn |
| Mar 31, 2025 | 2.81 Mn |
| Dec 31, 2024 | 22.73 Mn |
| Dec 31, 2024 | 22.73 Mn |
| Sep 30, 2024 | 4.03 Mn |
| Sep 30, 2024 | 4.03 Mn |
| Jun 30, 2024 | -10.95 Mn |
| Jun 30, 2024 | -10.95 Mn |
| Mar 31, 2024 | -14.53 Mn |
| Mar 31, 2024 | -14.53 Mn |
| Dec 31, 2023 | -132.64 Mn |
| Dec 31, 2023 | -132.64 Mn |